Belite Bio (BLTE) to Release Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE) is scheduled to be releasing its earnings data after the market closes on Monday, August 12th. Analysts expect Belite Bio to post earnings of ($0.28) per share for the quarter.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Trading Up 0.1 %

BLTE stock traded up $0.06 during trading on Tuesday, hitting $46.10. 13,965 shares of the company’s stock were exchanged, compared to its average volume of 55,576. The business has a 50-day moving average price of $48.40 and a two-hundred day moving average price of $44.80. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -38.30 and a beta of -1.47. Belite Bio has a 52-week low of $20.32 and a 52-week high of $50.66.

Analysts Set New Price Targets

BLTE has been the subject of several research analyst reports. Benchmark restated a “buy” rating and issued a $57.00 target price on shares of Belite Bio in a report on Thursday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $59.00 price objective on shares of Belite Bio in a report on Thursday, June 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Belite Bio in a report on Thursday, June 20th.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.